Skip to content
Strategic Partnering
News
Contact Us
Menu
Strategic Partnering
News
Contact Us
Invest
Disease Areas
Topical Scarring & Burns
Organ Fibrosis
Autoimmune Disorders
Wrinkles & Rhytids
Our Science
Kynurenic Acid MoA
Immune Cells Therapy
University of British Columbia
Products & Pipeline
Topical Creams
Systemic Administration
One-Time Delivery of APCs with KynA
About Us
Our Mission
Leadership
Grants
Menu
Disease Areas
Topical Scarring & Burns
Organ Fibrosis
Autoimmune Disorders
Wrinkles & Rhytids
Our Science
Kynurenic Acid MoA
Immune Cells Therapy
University of British Columbia
Products & Pipeline
Topical Creams
Systemic Administration
One-Time Delivery of APCs with KynA
About Us
Our Mission
Leadership
Grants
Disease Areas
Topical Scarring & Burns
Organ Fibrosis
Autoimmune Disorders
Wrinkles & Rhytids
Our Science
Kynurenic Acid MoA
Immune Cells Therapy
University of British Columbia
Products & Pipeline
Topical Creams
Systemic Administration
One-Time Delivery of APCs with KynA
About Us
Our Mission
Leadership
Grants
Strategic Partnering
Contact Us
Menu
Disease Areas
Topical Scarring & Burns
Organ Fibrosis
Autoimmune Disorders
Wrinkles & Rhytids
Our Science
Kynurenic Acid MoA
Immune Cells Therapy
University of British Columbia
Products & Pipeline
Topical Creams
Systemic Administration
One-Time Delivery of APCs with KynA
About Us
Our Mission
Leadership
Grants
Strategic Partnering
Contact Us
BirchBioMed Receives Health Canada Green Light to Start the Last Stage of its Groundbreaking Clinical Program of FS2 to Minimize Scarring from Burns
Press Release - BirchBioMed_Nutrasource CTA for Burn Trial
